Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

(2019) Kevin L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 American College of Rheumatology Recommended Patient‐Reported Functional Status Assessment Measures in Rheumatoid Arthritis

(2019) Claire E. H. Barber et al.   ARTHRITIS CARE & RESEARCH

A randomized trial of a motivational interviewing intervention to increase lifestyle physical activity and improve self-reported function in adults with arthritis

(2018) Abigail L. Gilbert et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis

(2017) Ernest H S Choy et al.   RHEUMATOLOGY

Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial

(2015) Tsutomu Takeuchi et al.   Modern Rheumatology

IL-6 as a keystone cytokine in health and disease

(2015) Christopher A Hunter et al.   NATURE IMMUNOLOGY

Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials

(2015) Ana-Maria Orbai et al.   Current Rheumatology Reports

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

(2014) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Discovery and characterization of olokizumab

(2014) Stevan Shaw et al.   mAbs

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years

(2011) M. U. Rahman et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

(2011) Yusuf Yazici et al.   ANNALS OF THE RHEUMATIC DISEASES

Quality of life and the outcome of established rheumatoid arthritis

(2011) Gabrielle Kingsley et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

IL-6/IL-6 receptor system and its role in physiological and pathological conditions

(2011) Masahiko Mihara et al.   CLINICAL SCIENCE

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate

(2010) Yasuharu Nakashima et al.   Modern Rheumatology

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

(2009) Jean-Michel Dayer et al.   RHEUMATOLOGY

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM